Background: Prostate-specific membrane antigen (PSMA) is frequently overexpressed and upregulated in prostate cancer. To date, various
Background
Prostate cancer is among the most common malignancy in men in Western countries and accounts for the fifth leading cause of cancer-related death in men [1] . This situation clearly underscores prostate cancer as a highly frequent but still unmet medical challenge which continues to be the target of a significant proportion of current clinical research, including to a large extent the development of novel radiotracers for positron emission tomography (PET) imaging of prostate cancer [2, 3] . PET imaging of prostate cancer was successfully demonstrated with various 11 C-and 18 F-labeled choline analogs, as well as 11 C-acetate for imaging cell membrane and fatty acid metabolism in prostate cancer [4, 5] . PET imaging of prostate cancer with [ 18 F]FDG, the most widely used radiopharmaceutical for cancer imaging, gave mixed results. [
18 F]FDG-PET is not useful in the detection of primary organ-confined prostate cancer and local recurrences after radical prostatectomy, as well as in differentiating between post-operative scar and local recurrence. However, [ 18 F]FDG uptake in prostate cancer was reported to correlate with prostate-specific antigen (PSA) level as a biomarker to measure tumor aggressiveness [6] . [ 18 F]FDG-PET was also used to monitor therapeutic response of patients with androgen-independent disease [7, 8] .
The aforementioned limitations of [ 18 F]FDG-PET in connection with the importance of prostate cancer as a significant unmet clinical need drive current developments towards targeted molecular imaging of prostate cancer. One prominent class of agents that exemplifies the outcome of this effort includes radiotracers targeting the trans-membrane protein, prostate-specific membrane antigen (PSMA) [9] . PSMA is a highly promising biomarker for targeted prostate cancer imaging due to its elevated expression and up-regulation in poorly differentiated, metastatic, and androgen-independent carcinomas.
PSMA is a particularly important molecular target in prostate cancer patients with negative bone scans who are at high risk for metastatic disease. Moreover, PSMA is an ideal target for developing small-molecule radiopharmaceuticals which typically show fast blood clearance and low background activity [9] . Over the past decade, several urea-based and phosphoramidate peptidomimetic inhibitors of PSMA have been developed and labeled with positron emitters such as 11 C, 18 F, 68 Ga, 64 Cu, 124 I, and 86 Y [9] . Among these small-molecule PSMA-imaging agents, especially 68 Ga-labeled compounds have been introduced into clinical applications for PSMA imaging in prostate cancer patients [10, 11] . Although 68 Ga-labeled small-molecule PSMA inhibitors exhibit favorable clinical imaging properties, improved lesion detection could be further enhanced using 18 F due to its lower positron energy and longer half-life, or improved retention due to the chemical nature of existing agents. This was recently demonstrated by the first comparative clinical study of 18 F-labeled PSMA inhibitor [ 18 
F]DCFPyL with [
68 Ga]Ga-PSMA-HBED-CC [12] .
Another challenge associated with 68 Ga-labeled radiopharmaceuticals for clinical imaging is the less than optimal availability of 68 Ga generators, especially with respect to their regulatory status in North America. Given the small quantity of 68 Ga eluted from 68 Ga generators (typically up to 1850 MBq), producing more than 1-3 doses per production batch is also challenging, which increases production costs.
However, despite the inherent advantages of 18 F like the favorable physical half-life of 109.8 min and the convenient availability as cyclotron-produced [
18 F]fluoride at high specific activity, the production of 18 F-labeled small-molecule PSMA inhibitors is complicated and often low yielding [13] [14] [15] [16] [17] [18] [19] [20] .
In all cases, radiosyntheses were accomplished via challenging prosthetic group-based multi-step synthesis routes or aluminum- solution and Chromafix (30-PS-HCO3, Macherey-Nagel) cartridges were purchased from ABX. All other chemicals and solvents were purchased from Sigma-Aldrich. All solvents were dried and/or distilled prior to utilization.
1 H-NMR and 13 C-NMR spectra were recorded on an Agilent/Varian Inova two-channel 400-MHz spectrometer, an Agilent/Varian Inova four-channel 500-MHz spectrometer, and an Agilent/Varian VNMRS threechannel 600-MHz spectrometer. Chemical shifts are given in parts per million (ppm) referenced to internal standards (s = singlet, bs = broad singlet, d = doublet, dd = doublet of doublet, ddd = doublet of doublet of doublet, t = triplet, M = multiplet, m = massif). Mass spectra were recorded using a Micromass ZABSpec Hybrid Sector-TOF by positive mode electrospray ionization. High resolution mass spectra (HRMS) were carried out on an Agilent Technologies 6220 oaTOF. Crude reaction mixtures were analyzed by TLC and HPLC. Thin-layer chromatography (TLC) was monitored using HF254 silica gel. HPLC analyses were performed on a semi-preparative Luna C18 column (100 Å, 10 μm, 250 × 10 mm) or Jupiter C12 (100 Å, 10 μm, 250 × 10 mm).
Both columns were connected to their corresponding guard columns (Phenomenex Nucleosil LUNA (II) RP C18 pre-column (5 μm, 50 × 10 mm) and Jupiter C12 pre-column (5 μm, 50 × 10 mm)). UV detection was performed at 210 and 254 nm. Radioactivity detection was achieved using a well-scintillation NaI (Tl) detector.
[ 18 F]Fluoride was produced by the 18 O(p,n) 18 F nuclear reaction through proton irradiation of enriched (98 %) 18 O water (3.0 mL, ROTEM, Germany) using a TR19/9 cyclotron (Advanced Cyclotron Systems, Inc., Richmond, BC, Canada).
Chemical synthesis
One hundred fifty milligrams (0.507 μmol) of Glu(O t Bu)-O t Bu·HCl 1 was dissolved in 2 mL of freshly distilled CH 3 CN. Seventy microliters of Et 3 N (0.507 μmol) and 142 mg (0.554 μmol) of N,N′-disuccinimidyl carbonate was added to the solution. The reaction was stirred at 25°C for 12 h and concentrated under reduced pressure. After resolubilization in 5 mL of EtOAc and successive washing with 10 mL of 10 % citric acid and 10 mL of brine, the organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure to afford 197 mg of a pale yellow powder. This unpurified powder contained 90 % of desired compound 2 (yield 78 %). TLC: (EtOAc/hexane, 3/1): R f = 0.7. 
Compounds 4 and 5 and DCFPyL were previously synthesized [15, 16] One gram (6.34 mmol) of 6-chloronicotinic acid 7; 1.1 g (6.5 mmol) of 2,3,5,6 tetrafluorophenol; and 1.31 g (6.34 mmol) of N,N′-dicyclohexylcarbodiimide (DCC) were stirred in dioxane (40 mL) for 5 h at 25°C. Progress of the reaction was monitored by TLC (EtOAc/hexane 4/1). Upon completion, the reaction mixture was filtered and concentrated under reduced pressure and the residue was purified by recrystallization in hot hexane to afford 1.35 g (70 %) of the 6-chloronicotinic acid active ester intermediate as a white powder [18] . TLC: (EtOAc/hexane 4/1): R f = 0.28. [18] was dissolved in 3 mL of a 1 M Me 3 N solution in THF and stirred 2 h at 25°C. After 5 min, a white precipitate was formed. After completion of the reaction, the precipitate was collected by filtration and washed with diethyl ether and cold CH 2 Cl 2 . The obtained white powder was suspended in 5 mL of CH 2 Cl 2 containing 2 % TMSOTf and sonicated for 10 min. The reaction mixture was concentrated under reduced pressure and washed with diethyl ether to afford 140 mg (68 % over two steps) of a gray powder after drying. 
To a solution of 80 mg (164 μmol) of compound 5 in CH 2 Cl 2 (4 mL) was added compound 8 (100 mg, 209 μmol) and 100 μL of DIPEA (572 μmol). The reaction was stirred for 2 h at 25°C and then concentrated under reduced pressure.
Progress of the reaction was monitored by TLC: (CH 2 Cl 2 /MeOH 4/1): R f = 0.26. HPLC purification was performed on a semi-preparative Jupiter C12 column (100 Å, 10 μm, 250 × 10 mm). The eluting solvent started with a gradient from 5/95 to 70/30 acetonitrile/(water 0.5 % TFA) for 20 min at a flow rate of 2 mL min −1
. Then the eluent was kept at 70/30 acetonitrile/(water 0.5 % TFA) for 10 min to elute the desired compound at 25.8 min. After removal of the solvent under reduced pressure gave 96 mg (77 %) of desired compound 9 as a white powder. Fig. 3 ). The synthesis unit was installed and operated in a shielded hot cell.
Analytical HPLC was carried out using a Gilson HPLC (Mandel Scientific Company Inc.; Guelph, Ontario, Canada) by injection of HPLC-purified [ 18 F]DCFPyL onto a Phenomenex Nucleosil Luna C18 column (10 μm, 250 × 10 mm) and elution with 20 % CH 3 CN/0.2 % TFA for 5 min at 2 mL min , followed by gradient elution from 20 % to 38 % CH 3 CN for 5 min and from 38 % to 70 % CH 3 CN for 15 min with isocratic elution at 70 % CH 3 CN for 15 min. Radio-TLC analysis on silica gel plates gave a R f value of 0.6 in 95 % CH 3 CN/H 2 O (Additional file 1: Figure S4 ). (Fig. 3) . The synthesis unit was installed and operated in a shielded hot cell.
In vivo tumor models
All animal experiments were carried out in accordance with the guidelines of the Canadian Council on Animal Care (CCAC) and approved by the local animal care committee (Cross Cancer Institute, University of Alberta).
PET imaging experiments were carried out in LNCaP and PC3 tumor-bearing Balb/c nude mice (Charles River Laboratories, Quebec, Canada). Male Balb/c nude mice were housed under standard conditions with free access to standard food and tap water. 
Dynamic PET imaging
General anesthesia of tumor-bearing mice was induced with inhalation of isoflurane in 40 % oxygen/60 % nitrogen (gas flow = 1 mL min −1 ), and the mice were subsequently fixed in prone position. The body temperature was kept constant at 37°C for the entire experiment. The mice were positioned in a prone position into the center of the field of view. A transmission scan for attenuation correction was not acquired. The mice were injected with 2-10 MBq of [ Mean standardized uptake values [SUV] mean = (activity/ mL tissue)/(injected activity/body weight), mL/g, were calculated for each ROI. Time-activity curves (TACs) were generated for the dynamic scans only. All semi-quantified PET data are presented as means ± SEM. Statistical difference for the blocking study was tested by unpaired Student's t test and was considered significant for P < 0.05.
Internalization experiments

10
5 LNCaP or PC3 cells were seeded in poly-D-lysinecoated 12-well plates 24-48 h before the assay so that cells could reach 95 % confluency. The medium was removed 1 h before the assay, and the cells were rinsed twice with PBS. After the addition of Krebs buffer (1 mL) to each well, the cells were incubated at 37°C. Krebs buffer was aspirated, and the cells were incubated with 300 μL of [
18 F]DCFPyL in 0.9 % NaCl (0.1 MBq )
for 60 min at 37°C. Cellular uptake was stopped by removing incubation media from the cells and washing the wells twice with ice-cold PBS buffer (1 mL). Surfacebound radioactivity was removed from the cells through incubating the cells twice with 0.5 mL glycine-HCl in PBS (50 mM, pH 2.5) for 5 min at 37°C. Cells were washed again with ice-cold PBS before the addition of radio-immunoprecipitation assay (RIPA) buffer (400 μL) to lyse the cells. Cells were returned into the incubator for 10 min, and cell lysates were collected for counting. Radioactivity of surface-bound and internalized fraction was measured in a WIZARD2 Automatic gamma counter (Perkin Elmer, Waltham, MA, USA). Total protein concentration in the samples was determined by the bicinchoninic acid method (BCA; Pierce, Thermo Scientific 23227) using bovine serum albumin (800, 600, 400, 300, 200, 100, 50 μg/mL, blank) as protein standard. Data are expressed as percent of total uptake per 1 mg protein (% of total uptake/mg protein).
Tracer kinetic analysis
Tracer kinetic analysis was performed using a two-tissue compartmental model using dynamically acquired PET imaging data. Full details on tracer kinetic analysis are given in the Additional file 1.
Results
Chemistry and radiochemistry
Synthesis of lysine-urea-glutamate peptidomimetics as highly potent PSMA-binding motifs is given in Fig. 2 . Compounds 4, 5, and DCFPyL were previously described in the literature [15, 16] . Herein, we present an improved synthesis route [15, 16] . Synthesis commenced with the activation of tert-butyl ester protected amino acid H-Glu(O t Bu)-O t Bu.HCl 1 with N,N′-disuccinimidyl carbonate to give corresponding NHS ester (S)-(1,5-di-tert-butoxy-1,5-dioxopentan-2-yl)carbamic acid 2 in 87 % yield. Coupling of active ester 2 with μ-benzyloxycarbonyl-L-lysine tert-butyl ester (HLys(Z)-O t Bu.HCl) 3 afforded 2-(3-{1-tert-butylcarboxylate-5-[(carboxybenzyl)-amino]-pentyl}-ureido)-di-tertbutyl pentanedioate 4 in 92 % yield. Removal of the Z protecting group in compound 4 using hydrogenation on Pd/C gave 2-{3-[1-tert-butylcarboxylate-(5-aminopentyl)-ureido}-di-tert-butyl pentanedioate 5 in high chemical yields of 95 %.
The free amine in 5 was acylated with 6-fluoronicotinic acid 6 in the presence of HBTU followed by acidic cleavage of tert-butyl ester groups using trifluoroacetic acid (TFA) to give reference compound 2-(3-{1-carboxy-5-[(6-fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPyL) in 53 %. The total yield for the four step synthesis of DCFPyL was 40 %. Trimethylammonium salt 9, which was the precursor for direct radiofluorination, was prepared by acylation reaction of compound 5 with active ester N,N,N-trimethyl-5-((2,3,5,6-tetrafluorophenoxy)carbonyl)-pyridin-2-aminium triflate 8. Active ester 8 was prepared with slight modifications based on a published procedure [21] in 68 % yield in two steps starting from 6-chloronicotinic 6 acid. Activation with 2,3,5,6-tetrafluorophenol gave compound 7 which was treated with trimethylamine followed by TMSOTf to afford compound 8. Compound 9 was obtained through reaction of compound 5 with active ester 8 in 77 % yield after purification by HPLC.
Automated radiosynthesis of [ 18 F]DCFPyL was performed on a GE TRACERlab TM FX FN automated synthesis unit (ASU) equipped with an integrated HPLC system using a Luna semi-prep HPLC column (Fig. 3) .
The overall radiosynthesis of [ 18 F]DCFPyL is displayed in Fig. 4 , and the optimized HPLC purification is given in the supplementary materials (Additional file 1: Figure S3 ).
In the first reaction step (R1), cyclotron-produced nocarrier added (n.c.a.) [ 18 F]fluoride was captured from The second reaction (R2) involved combining n.c.a. [ 18 F]fluoride and 9 to form compound 10 via a nucleophilic heteroaromatic substitution reaction. Radiofluorination was carried out with 5 mg of labeling precursor 9 in anhydrous CH 3 CN (0.5 mL) at 60°C for 10 min.
Final reaction step (R3) included removal of the tert.-butyl ester protecting groups in compound 10 via acidic cleavage using 1.5 mL of HCl (10 N) in 1 mL CH 3 CN at 40°C for 5 min to give crude [ 18 F]DCFPyL. The pH of the crude reaction mixture was adjusted by the addition of 2 mL of 0.1 M NaOAc (pH 5.8), and the reaction mixture was transferred into a 5-mL injection loop and injected onto a Luna C-18 column (10 μm, 250 × 10 mm) for purification employing isocratic elution with 18 % EtOH containing 0.2 % H 3 PO 4 at a flow rate of 2 mL min −1
. Product peak was collected between 22 and 23 min (Additional file 1: Figure S3 ). The collected peak (~2 mL) was transferred, through a sterile filter, into a sterile vial containing 12 mL of 0.1 M NaOAc (pH 5.8).
The total synthesis time was 55 min, including HPLC purification. The overall isolated radiochemical yield of [ 18 F]DCFPyL was 23 ± 5 % (n = 10, decay-corrected).
Quality control of [ 18 F]DCFPyL
Identity of [ 18 F]DCFPyL was confirmed by radio-HPLC and radio-TLC using co-injection and co-spotting with reference compound [ 19 F]DCFPyL, respectively. Representative HPLC traces are given in Fig. 5a . Quality control revealed high radiochemical purity of 98 %, and the Figure S4 ), and the product was stable (>95 %) in saline of up to 4 h.
Cell-specific internalization experiments
Radiotracer [
18 F]DCFPyL revealed substantial higher cell membrane accumulation and internalization in PSMA+ LNCaP cells compared to PSMA− PC3 cells (Fig. 6) . After incubation for 60 min, cellular uptake of [ 18 F]DCFPyL was stopped and cells were washed with glycine-HCl to remove radioactivity bound to the membrane. Internalized fraction of radioactivity was determined after lysing the cells with RIPA buffer. After 60 min, radioactivity uptake in PSMA+ LNCaP cells reached 45.47 ± 1.01 % of total uptake/mg protein for the membrane-bound fraction and 35.05 ± 0.69 % of total uptake/mg protein for the internalized fraction. This reflects a 44 % fraction of internalized radioactivity in PSMA+ LNCaP cells after incubation with radiotracer [ 18 F]DCFPyL for 60 min. In contrast, only 4.30 ± 0.40 % of total uptake/mg protein and 0.76 ± 0.05 % of total uptake/mg protein were found in the membranebound and internalized fraction, respectively, in the case of PSMA− PC3 cells.
Dynamic PET imaging experiments
Radiotracer [
18 F]DCFPyL was injected into PSMA+ LNCaP and PSMA− PC3 tumor-bearing BALB/c nude mice. As shown in Fig. 7 , high radioactivity uptake and retention was observed in the PSMA+ LNCaP tumor, whereas only very In contrast, PSMA− PC3 tumors showed some radioactivity uptake during the perfusion phase followed by rapid washout of radioactivity reaching a SUV of 0.1 (n = 2) at 60 min p.i..
In both prostate cancer models, radioactivity is rapidly cleared from blood and muscle. Radiotracer [ 18 F]DCFPyL is eliminated through the kidneys with somewhat more retention of radioactivity in the kidneys in the PC3 model.
Only very little radioactivity is found in all other organs resulting in a low background signal. Rapid clearance from blood and muscle tissue led to high tumor-to-blood and tumor-to-muscle ratios of 8.9 ± 1.9 and 17.0 ± 3.4, respectively, after 60 min p.i. in LNCaP-bearing mice.
Specificity of radiotracer [
18 F]DCFPyL for PSMA was demonstrated through blocking experiments in the LNCaP model. LNCaP PSMA+ model was injected with 300 μg of nonradioactive DCFPyL 5 min prior to the administration of radiotracer [
18 F]DCFPyL. Control and blocking experiments were carried out in the same animal on 2 consecutive days.
Acquired PET images confirmed substantial decrease of radioactivity uptake in the LNCaP tumor, which was statistical significant (P = 0.0069). Radioactivity uptake was reduced by 80 % after 60 min p.i. upon pretreatment with DCFPyL (SUV 60min control: 1.1 ± 0.1, n = 5; SUV 60min blocked: 0.2 ± 0.05, n = 4). Uptake in the kidneys was also reduced (Fig. 8) .
In vivo metabolic stability of [
F]DCFPyL
18 F]DCFPyL was studied by analyzing murine blood samples at different time points and urine after 60 p.i. using radio-HPLC. Figure 9 summarizes the results reflecting the distribution pattern of radioactivity in blood cells, plasma proteins, and plasma over time. The overall distribution of radioactivity in the different blood compartments remained mainly unchanged over time, suggesting rapid equilibration of radioactivity distribution between analyzed blood compartments. The majority of radioactivity is found in the plasma fraction indicating high bioavailability of radiotracer [ High stability of [ 18 F]DCFPyL was also found in urine samples after 60 min p.i. In all cases, no radiometabolites were detected in plasma and urine samples over the studied time course of 60 min p.i. Fig. 7 ). Four kinetic parameters (K 1 , k 2 , k 3 , k 4 ) describing the flow of the radiotracer from the blood to the tissue (K 1 ) and from the tissue into the blood (k 2 ), binding of the radiotracer to the tissue (k 3 ) and dissociation from the tissue (k 4 ), were calculated.
The analysis was performed by fitting the measured TACs with a two-exponential model of the general form as described, e.g., by van den Hoff (Additional file 1: Figure S2 ) [22] . Results for the four kinetic parameters are given in Fig. 10 .
The net delivery (K 1 /k 2 ) of the radiotracer to the tissue was comparable for LNCaP (K 1 /k 2 = 0.62) and PC3 (K 1 / k 2 = 0.49) tumors. However, radiotracer [ 18 F]DCFPyL accumulated significantly (10.25 times) more in PSMA+ LNCaP tumors compared to PSMA− PC3 tumors (k 3 (LNCaP) 0.082 vs. k 3 (PC3) 0.008). The coefficient k 3 / (k 3 + k 2 ) describes the fraction of radiotracer entering the second compartment (i.e., being bound as opposed to being released back into the blood pool): the value for LNCaP (0.314) dominates that of PC3 (0.058) by more than a factor 5. Significant differences were also found in the dissociation rate (k 4 
Discussion
The present study described the automated radiosynthesis and preclinical validation of (S)-2- The following important results emerged from this study: [1] [12, 13] . In one case, the radiosynthesis was carried out in a modified dual-run FDG synthesis module [13] applications and advantages of this methodology for the design and synthesis of numerous 18 F-labeled radiotracers have extensively been reviewed [23] . Building on this work, we envisaged a direct radiofluorination synthesis route based on 2-[ The use of trimethylammonium salt 9 as labeling precursor offers several advantages. Notably as a solid, compound 9 allows for convenient handling and storage. Compound 9 was stored at 4°C without significant decomposition for at least 3 months. Moreover, excellent leaving group properties of the Me 3 N group in heteroaromatic nucleophilic substitution reactions with n.c.a. [12, 13, 15] and should help ensure the availability of the agent. The specific activity was determined to be 80-100 GBq/μM. [15, 17, 18] .
As shown in was about 11 times higher compared to PSMA− PC3 tumors (SUV 60min = 0.1). After 60 min p.i., only some radioactivity was also found in the kidney with only very minimal background radioactivity in the liver. Most of the injected radioactivity was accumulated in the bladder after 60 min p.i.. This biodistribution profile is consistent with previously reported studies using [ 18 F]DCFPyL for PET imaging of PSMA in other prostate cancer models [15] . As expected for PSMA− PC3 tumors, only very little radioactivity was found in the tumor at 60 min p.i.. The highest levels of radioactivity in the PC3 model were also observed in the kidneys and bladder (Fig. 6) .
Renal clearance pathway as seen for urea-based peptidomimetic PSMA inhibitor [ 18 F]DCFPyL was also reported for 18 F-labeled phosphoramidate peptidomimetic as small-molecule PSMA-imaging agent in LNCaP-and PC3-bearing mice [18] . Uptake of radiolabeled phosphoramidate in PSMA+ LNCaP tumors was about four times higher compared to the uptake in PC3 tumors as determined by ex vivo biodistribution studies.
Favorable radiopharmacological profile and specificity of [ 18 F]DCFPyL for PSMA imaging in vivo was further 
